We describe here the development of a murine system for the identification of genes involved in myelomonocytic neoplasms. Transgenic C57BL/6J mice expressing SV40 early region under a myelomonocytic promoter develop histiocytic sarcomas with a latency of 167 days. We used retroviral proviral tagging to accelerate tumorigenesis and to uncover genetic changes that contribute to tumor development. Infection of transgenic mice with Friend murine leukemia virus (F-MuLV) shortened the latency of morbidity to 103 days (P Ͻ 0.001); this was associated with clonal proviral integrations in tumor DNA. As expected for F-MuLV, proviral insertions occurred at Fli1 in both transgenic and nontransgenic tumors. Four insertions were found at a novel locus, termed Fim4, on chromosome 6. This region is syntenic to human 7q32, a region that is commonly deleted in human myelodysplastic syndrome and acute myeloid leukemia. A murine BAC containing Fim4 was sequenced and analyzed, and while there was significant human-mouse homology in the area of the insertions, no candidate gene has been identified. Thus we have established a system to identify genes involved in myelomonocytic tumors, and have used it to identify Fim4, a new common site of proviral insertion. Study of this locus may provide insight into genes involved in AML-associated 7q32 deletions in humans.
Introduction
The development of malignancies in humans is the consequence of the cumulative effect of several genetic and epigenetic events that result in loss of control of cellular growth and differentiation. One common class of events in neoplastic transformation is the mutation or loss of tumor suppressor genes. The SV40 large T antigen protein promotes tumor formation through inhibition of several tumor suppressor proteins, including p53 1 and those in the Rb family. 2 Large T antigen can bind to and inactivate the function of Rb, causing the release of the transcription factor E2F from Rb. E2F that is free of Rb then activates genes involved in cell cycle progression, thus promoting cellular growth. T antigen can interact as well with other members of the Rb family of cell cycle control proteins, including p107 and p130. 3 The p53 protein plays a critical role in the response of cells to several different types of stress, including genotoxic stress and hypoxia (reviewed in Ref. 4) . Depending upon the stimulus and the cell type, p53 activation can lead to either cell cycle arrest 5 or cell death.
Using a transcriptional regulatory region from the gp91-phox gene, it has been possible to target SV40 large T antigen expression to myelomonocytic cells in transgenic mice, and to induce true histiocytic lymphomas that express markers of the macrophage/monocyte/histiocyte lineages. 8 These tumors arise at 6-12 months of age, depending on the transgenic line, and are confined to the abdominal cavity, where they can infiltrate the spleen, liver, uterus, mesentery, pancreas, and abdominal lymphatic system. In male mice of certain but not all transgenic lines, neuroblastomas arise in the prostate. 9 Given the 6-12 month latency associated with the development of the histiocytic neoplasms in gp91-phox-T antigen transgenic mice, we considered it likely that the expression of SV40 large T antigen in the myelomonocytic cells was necessary but not sufficient for tumor development, and that other genetic events were involved. The identification of these events would likely give us insight into tumor progression in the setting of the loss of p53 and Rb. Proviral tagging mutagenesis is a powerful method for the identification of oncogenes and tumor suppressor genes in retrovirally induced murine tumors. [10] [11] [12] In this study, we have employed proviral tagging to find genes that cooperate with SV40 large T antigen in the development of histiocytic sarcomas in gp91phox-SV40 early region transgenic mice. We show that Friend murine leukemia virus (F-MuLV) accelerates tumorigenesis in these mice, and that this is associated with the presence of clonal proviral insertions in the genomic DNA of the resultant tumors. By analysis of proviral integrations we have identified two genes that are candidate cooperating oncogenes: Fli1, which is known to cooperate with p53 loss in erythroleukemias, 13 and a novel gene, Fim4.
Materials and methods

Transgenic mice
Plasmid DNA construct having SV40 large T antigen under transcriptional control of the gp91-phox promoter (described in Ref. 8) was kindly provided by David Skalnik (Indiana University, Indianapolis, IN, USA). The 628 transgenic mouse line employed in these studies was derived using C3H/NxC57BL/6J F2 fertilized ova by standard techniques. 14 Transgenic founders were identified by Southern blot analysis of tail DNAs (5 g), digested with restriction enzymes as described. 8 Offspring of the 628 founder were genotyped by polymerase chain reaction, using primers 5Ј CAC-CACTGAATCCATTTTGGG 3Ј and 5Ј CTCTCAACA TTCTACTCCTC C 3Ј, which resulted in the production of an 861 mw band. Mice were fed ad libitum and were palpated for splenic enlargement on a weekly basis. Mice were killed when moribund, as noted by difficulty breathing, lethargic movements, or increased abdominal girth. Complete necropsies were performed on all mice with histopathologic analyses of all visceral and hematopoietic organs.
Retroviral infections and analysis of mice
F-MuLV supernatants were harvested from a mouse producer cell line, 15 filtered through a 0.45 micron filter, and frozen at −80°C in aliquots. The production of virus was confirmed by assays for reverse transcriptase, which were performed as described. 16 Mice were injected intraperitoneally with viral supernatant within 48 h of birth.
Southern blotting
High molecular weight DNA was prepared as described 17 from frozen tumor tissues. Ten microgram aliquots of tumor DNA were digested to completion with restriction enzymes (New England Biolabs, Beverley, MA, USA), fractionated on 0.9% agarose gels (FMC BioProducts, Rockland, ME, USA), and transferred to Zetabind nylon membranes (Amersham, Piscataway, NJ, USA) as described previously. 17 Probes for FMuLV envelope (from S Ruscetti, National Cancer Institute, Frederick, MD, USA, as a 0.57 kb BamHI fragment from plasmid p57B-B 15 ), Fli1 (from E Rassart, University of Quebec, Montreal, Canada, as a 1.4 kb EcoR1 fragment of SU11 18 ), IgH (from HC Morse III, National Institutes of Health, Bethesda, MD, USA, as JH J11 fragment) and Fim4 (see below) were labeled by a random priming-Klenow DNA synthesis reaction as described. 19 Hybridizations of Southern blots were performed at 65°C as described. 20 Filters were exposed to Xray film for 2-7 days.
Cloning of proviral insertions
Tumor DNA (100 g) was restricted partially with Sau3A1, and fractionated on a continuous sucrose gradient (10-40%) as described. 21 Fragments in the 16-25 kb size range were isolated, purified, and partially filled in with dGTP and dATP using Klenow fragment of E. coli DNA polymerase I in 1 × Klenow buffer (New England Biolabs). The DNA was purified, and ligated to lambda vector DashII arms (Stratagene, La Jolla, CA, USA), that had been XhoI-cut, partially filled in with dCTP and dTTP, and purified. The ligation (5 l reaction volume, 1 × ligase buffer (New England Biolabs), 15 h at 4°C) contained 500 ng of vector arms and 1 g of insert. The reaction components were then packaged, plated, screened, and subcloned as described 21 using an env fragment of F-MuLV as a probe.
Inverse PCR amplification of proviral insertions
Inverse PCR was performed as described. 10 Primers for primary and secondary PCR were designed based on the sequence of F-MuLV deposited in GenBank (Accession No. X02794) and are shown in Table 1 
BAC cloning and sequencing
Mouse genomic DNA for the Fim4 locus was isolated as a bacterial artificial chromosome (BAC) clone from RPCI23, a library of C57BL/6J DNA, by standard hybridization screening methods using filters from Research Genetics. Several BAC clones were identified, one of which, clone RPCI23-402k12, was sequenced in its entirety.
The detailed procedures for cloned, large insert genomic DNA isolation, random shot-gun cloning, fluorescent-based DNA sequencing and subsequent analysis were used as described previously. [22] [23] [24] Briefly, 50 g portions of purified BAC DNA were randomly sheared and made blunt-ended 21, 23 and ligated into SmaI-cut, bacterial alkaline phosphatase (BAP)-treated pUC18 (Pharmacia, Piscataway, NJ, USA), and E. coli were transformed by electroporation. A random library of approximately 1200 colonies was picked from each transformation, grown in Terrific Broth (TB) medium 21 supplemented with 100 g of ampicillin for 14 h at 37°C; sequencing templates were isolated by a cleared lysate-based protocol. 23 Sequencing reactions were performed as previously described 24 using Thermus aquaticus (Taq) DNA polymerase and the Perkin-Elmer Cetus fluorescently labeled Big Dye Taq terminators. After base calling with the ABI Analysis Software, the analyzed data was transferred to a Sun Workstation Cluster, and assembled using Phred and Phrap programs. 25, 26 Overlapping sequences and contigs were analyzed using Consed. 27 Gap closure and proofreading was performed using either custom primer walking or using PCR amplification of the region corresponding to the gap in the sequence followed by sub-cloning into pUC18 and cycle sequencing with the universal pUC-primers via Taq terminator chemistry. In some instances, additional synthetic custom primers were necessary to obtain at least three-fold coverage for each base.
Working draft and finished BAC sequences were analyzed on Sun workstations with the programs contained within the Genetics Computer Group package as well as the BLAST, 28 BEAUTY, 29 BLOCKS, 30 PIPMAKER 31 and DOTTER 32 programs. The sequence of BAC clone RPCI23-402k12 has been deposited into GenBank and given accession number AC024913.
Fluorescence in situ hybridization
Metaphase chromosomes from peripheral blood lymphocytes were prepared by standard methods. The BAC clone RP11-36B6 was labeled with digoxogenin-11-dUTP by nick-translation. Hybridization conditions, post-hybridization washes, and detection was performed as previously described. 33, 34 The digoxigenin-labeled probed was cohybridized with probe for centromere of chromosome 7. The metaphase spreads were Relative to bp+1 of the viral RNA, located at the 5Ј end of the R region in the 5Ј LTR, based on GenBank Sequence X02794.
imaged with a computer controlled Zeiss-Axiophot (Gö ttingen, Germany) epifluoresence microscope equipped with cooled charged coupled device camera. DAPI, FITC and Rhodamine images were captured individually using appropriate filters and the images were enhanced, pseudo-colored and merged automatically (Applied Imaging software, Santa Clara, CA, USA). More than 20 metaphases were analyzed for localizing the probe.
Results
Characterization of transgenic line 628
The gp91-phox-SV40 early region construct transgenic line 628 was identified as one out of 24 founder animals positive for transgene expression in spleen RNA (data not shown). A total of 31 mice (10 females and 21 males) from various generations from backcrosses to C57BL/6J were observed for tumor development. One hundred percent of this cohort of mice developed neoplastic disease with a median latency of 167 days with a spectrum of malignancy similar to that described previously. 8, 9 The lesions included histiocytic sarcomas, myeloid leukemias, or prostomas, with three mice developing more than one tumor ( Table 2 ). The histiocytic sarcomas appeared as invasive sarcomatous growths of histiocytic cells with pale-staining, vesicular cytoplasm involving the skin and subcutaneous tissue (Figure 1c) , spleen, liver (Figure 1a, b and d), mesentery, pancreas, abdominal lymph nodes, and subcutaneous tissues. In 6% (two out of 31) mice, there was myeloid leukemia involving the blood, spleen, bone marrow, and lymph nodes. Prostomas arose in 16 males, with a latency of 161 days.
Acceleration of tumorigenesis with F-MuLV
Given the 167 day latency for the development of a moribund state due to neoplastic disease, we considered it likely that Leukemia other events were necessary for tumorigenesis in this strain of mouse. Accordingly, we sought to identify these events by proviral tagging mutagenesis using the Friend murine leukemia virus, the helper virus component of the Friend virus complex. 35 Thirty neonatal transgenic offspring (16 N3 and 14 N4 mice) were injected with F-MuLV. In parallel, 56 nontransgenic siblings were injected as controls. Nineteen (12 females and seven males) of the 30 transgenic mice were killed when moribund and subjected to necropsy and histopathologic analysis; 11 were found dead. Of the nontransgenic, F-MuLVinfected cohort, 29 were killed when moribund and were analyzed. Southern blot analysis using KpnI to digest tumor DNAs (which cuts within the LTRs of the provirus) and the F-MuLV env gene as a hybridization probe, resulted in a single 9 kb band in 12 of the 19 transgenic tumors and 18 of the 29 nontransgenic tumors, thus revealing which tumors harbored FMuLV proviruses (Figure 2a ). Considering only these env-positive tumors the median latency of tumor development was 103 days for infected transgenic mice and 455 days for FMuLV-infected nontransgenic mice, which was significantly different (P Ͻ 0.001) (Figure 2b ). Among transgenic mice, virus-positive tumors developed significantly faster than uninfected tumors (103 days vs 167 days; P Ͻ 0.001; Figure 2b ).
Tumor diagnosis based on histopathology and Southern blotting for IgH rearrangement (for identification of B cell tumors) revealed that the F-MuLV-infected gp91phox-Tag mice had a different spectrum of disease than uninfected mice of the same genotype: F-MuLV infection of the male transgenic mice caused a marked shift from prostomas to histiocytic sarcomas in the male mice (Table 2; Figure 1 ). In addition, there was an incidence of myelomonocytic leukemia of 33% within the infected transgenic mice (Figure 1f showing involvement of spleen), while these occurred at an incidence of 6% in the uninfected transgenic mice. The predominant diagnosis in virally infected nontransgenic mice was myeloid leukemia (eight cases), presenting with markedly enlarged spleens showing infiltration of the red pulp with leukemia cells (Figure 1e) ; there was one case of histiocytic sarcoma. There were also eight cases of lymphoid neoplasms (four follicle center cell lymphomas, two thymic lymphoblastic lymphoma, one B cell lymphoblastic lymphoma, and one non-B cell splenic lymphoma).
Analysis of proviral insertions
To assess the clonality of proviral insertions acquired during tumorigenesis, we performed Southern blot analysis of DNAs digested with XbaI, which cuts once within the retrovirus (Figure 2c ). This revealed one or more env-hybridizing XbaIgenerated DNA fragments in most tumors, indicating multiple proviral insertions within the genomic DNA of the tumor.
Proviral insertion at Fli1
Previous data of Bernstein and coworkers suggest cooperativity between F-MuLV proviral insertions at Fli1 and mutations in p53. 13, 36 Given that the SV40 large T antigen can inactivate p53 function, we screened for insertions at Fli1 in F-MuLVinduced transgenic histiocytic sarcomas and myeloid leukemias by digesting tumor DNAs with KpnI and hybridizing Southern blots with SU11, a 1.4 kb EcoR1 fragment from the murine Fli1 locus. 37, 38 These analyses showed somatic alterations at Fli1 that are consistent with proviral insertions in tumor No. 111, which arose in the F-MuLV-infected transgenic mice (data not shown) and in tumor No. 155, an F-MuLV-induced tumor from nontransgenic animals (Figure 2d ). We also performed inverse PCR on tumor No. 474, which revealed a proviral insertion at Fli1 (data not shown). Thus, two transgenic tumors and one nontransgenic tumor harbor insertions at Fli1.
Isolation and characterization of proviral insertion at a novel common site of insertion, Fim4
To further assess sites of proviral insertion, we used lambda DNA cloning to isolate such sites from transgenic tumor 474. This resulted in isolation of a genomic fragment flanking one such insertion site, termed Fim4 (for Friend virus insertion in myelomonocytic tumor site 4). This DNA fragment was used to screen the other F-MuLV-induced tumors for proviral insertions, which revealed insertions in one nontransgenic tumor (No. 155; Figure 3a ) and one that arose in mouse No. 382, a nontransgenic mouse (data not shown). Thus, this locus is a common site of proviral insertion making it likely that the insertions at this locus are causally involved in tumorigenesis. Fim4 (insertions A and B, Figure 3c ).
By inverse PCR, we found that tumor No. 155 harbors two insertions in
With the goal of identifying a gene at the Fim4 locus, we isolated a bacterial artificial chromosome for the locus from a library of mouse strain 129 genomic DNA. This yielded several positive clones, one of which (RPCI23-402K12) was sequenced in its entirety (GenBank Accession No. AC024913). Analysis of this sequence revealed several candidate genes that are currently under study (Figure 3c ). Blast analysis of the RP23-402k12 sequence against human genomic DNA revealed significant homology to human BAC RP11-36b6 (GenBank Accession No. AC016831) located on human chromosome 7q32. This region is syntenic with mouse chromosome 6 in the area encompassing the leptin gene. No previously characterized oncogenes or tumor suppressor genes have been mapped to this area, indicating that Fim4 is a novel locus.
Analysis of the murine Fim4 locus
With the goal of identifying a gene at the Fim4 site of proviral insertion, we analyzed both the human and the mouse Fim4 genomic sequences to a greater extent. This failed to reveal any obvious protein-encoding gene within the area (Figure  3c ), despite the significant degree of conservation of DNA sequence between mouse and human (Figure 3b) . However, the homology is interrupted with sections of low homology, suggesting that this region plays a regulatory function rather than a protein-encoding function.
Analysis of the human Fim4 locus
To confirm that the Fim4 locus was localized to human chromosome 7q, we performed fluorescence in situ hybridization (FISH). Two BACs, one that contained sequences homologous to the Fim4 sequences (BAC RP11-36B6) and one for human 20 The wild-type allele is represented by a Ͼ23 kb band seen in the control DNA, while the provirally activated allele in tumor 155 is 4.5 kb (arrow to the right). chromosome 7 centromere were labeled with digoxygenin and biotin, respectively, and were hybridized to normal human metaphase chromosomes, and to metaphases from a leukemic patient having a monosomy 7. In both cases, both probes hybridized to the same chromosome, with the Fim4 BAC hybridizing to the long arm of the chromosome ( Figure  4a ). In the leukemia patient case, only a single chromosome was found to have a fluorescence hybridization signal, consistent with the diagnosis of monosomy 7 (Figure 4b ).
Discussion
A critical step in achieving a mechanistic understanding of leukemia is knowledge of all of the genes that can and do contribute to malignant transformation. In this paper we describe a system in which we can expect to identify genes through proviral tagging mutagenesis that, when deregulated, play a cooperative role in leukemic transformation. Our model has several distinctive features that set it apart from other animal models of leukemia (eg Refs 10, 39, 40) . First, to achieve proviral mutagenesis, we have utilized a unique combination of retrovirus and mouse strain: F-MuLV and C57BL/6J mice. Due to the presence in C57BL/6J of the Fhe locus, this strain is resistant to Friend-induced erythroleukemias. 35, 41 Use of this combination of mouse strain and virus for performing tumor acceleration studies and for cloning of proviral integrations has not been previously reported.
Leukemia
A second unique feature of our system is that we have used a transgenic mouse line that expresses SV40 large T antigen under control of a myelomonocytic transcriptional control region. This transgene, consisting of a 2.6 kb 5Ј-flanking region from the gp91phox gene fused to the early region of SV40, drives expression in histiocytic and monocytic/macrophage-like cells, 8 while expression of the transgene in granulocytic cells, which show the highest levels of endogenous gp91phox expression, is undetectable, 8 due to the absence of a critical granulocyte-specific transcriptional control region on the 2.6 kb promoter which has been located Ϸ30 kb upstream of the transcription start site. 42 Infection of these mice with F-MuLV results in a unique spectrum of tumor types that is distinct from that seen in uninfected 628 mice, as well as F-MuLV-infected C57BL/6J mice: in mice with both transgene and F-MuLV, there were few prostomas (one in six males), compared with the 66% incidence in uninfected 628 mice. In addition, compared with the incidence in uninfected 628 mice, there was an increase in the incidence of myeloid leukemias in both sexes (from 2/31 mice to 4/12 mice), and an increased incidence of histiocytic sarcomas in the males (Table 1) . Compared with infected nontransgenic mice, the FMuLV-infected 628 mice had a higher incidence of histiocytic sarcoma (nine in 12 mice compared with one in 18 mice). Thus it appears likely that in the 628+F-MuLV cohort, F-MuLV can infect and effectively mutagenize the same cell type that gives rise to the gp91phox-SV40 early region-induced histiocytic sarcomas. This gives us the unique opportunity to ident- ify new genes (by the cloning of proviral insertion sites) involved in histiocytic sarcomas, a tumor type whose genetic basis remains poorly understood.
We report the cloning of Fim4 in this manuscript, a site of proviral insertion that has not been observed in AKXD, BXH2, or CasBr virus-infected NFS mice. 10, 37, 39 Four proviral insertions within a Ϸ2kb region at Fim4 were identified in three tumors; one tumor, No. 155, had two insertions at Fim4. Both transgenic and nontransgenic tumors had insertions at Fim4, so unless SV40-independent interruption of p53 and/or Rb pathways occurred in the nontransgenic tumors, we cannot assert that Fim4 alteration specifically correlates with loss of p53 and/or Rb function. Despite the relatively tight clustering of the four proviral insertions at the Fim4 locus, there is no obvious gene in the area to clearly explain a link to growth deregulation. In humans, the region does have a CpG island (12.5 kb centromeric to the region of the insertions), a feature often found at the 5Ј end of functional genes. In addition, the region exhibits a high degree of overall similarity with the syntenic region of human DNA (Figure 3b) , suggesting evolutionary conservation that would be consistent with this area performing essential biologic function. Further mutagenesis will be necessary to uncover this function.
The human FIM4 locus is on human 7q32.2-32.3 ( Figure  4c ). Acute myeloid leukemia and myelodysplastic syndrome, especially those that occur secondary to genotoxic chemotherapy, are associated with deletions on the 7q region ( Figure  4c) , consistent with the existence on 7q of one or more tumor suppressor genes (TSG). To characterize the regions of loss, both FISH 43 and loss of heterozygosity studies [44] [45] [46] [47] [48] have been performed on cases of MDS and AML. These data have proven to be complex, with regions of loss commonly extending over a considerable portion of chromosome 7, from 7q21.3 to 7q33 and beyond. There appear to be three distinct areas of chromosome loss on 7q: one in 7q22, one at 7q31.1, and one at 7q32-33. One region of loss, at 7q31.1, is commonly lost in other malignancies such as breast, prostate, colon, and ovary (reviewed in Ref. 45 ); ST7, a tumor suppressor gene, has recently been identified in prostate cancer and is located in this area. This is likely one contributory gene. 49 However, mutations of ST7 in cases of human leukemia and MDS have not been investigated. Despite the likelihood that ST7 is a TSG within one area of minimal deletion and is probably involved in certain cases of MDS and AML, it is also likely that other regions are involved, particularly on 7q22 and 7q32-33. Unfortunately, in most of the published analyses, the deletions on 7q are large and encompass the entire region from 7q22 to 7q34 or beyond. Informative patients are few, making it difficult to localize the minimal regions of loss. Le Beau et al, 43 by FISH analysis of AML and MDS cases using YAC clones from 7q as probes, identified a commonly deleted region of 7q at bands 32-33 that would encompass FIM4 which is located on 7q32.2-7q32.3 ( Figure 4c ). Koike et al 45 analyzed two cases (patients 16 and 5, Figure 4c ) with deletions that could encompass FIM4; however, critical markers in the area of FIM4 were nonpolymorphic, precluding a conclusive assessment. They also reported one patient ( Figure  4c , patient 7) with deletion of D7S505 and D7S498, but normal DNA proximal and distal to this at D7S500 and D7S550; this region may yet harbor a distinct TSG, but with only one patient having such a deletion, it is difficult to assess. In a study by Kere and coworkers, three informative patients were analyzed (Figure 4c) . 46 One patient (No. 3, Figure 4c ) had a deletion that would encompass FIM4, while two (Nos 1 and 2) had endpoints of deletion centromeric of FIM4, suggesting that FIM4 was outside the deleted region. It is possible, however, that the deletions in patients 1 and 2 were selected for due to loss of ST7, while in case 3 the deletion was selected due to loss of both genes.
In summary, it is difficult to make a firm case for or against the involvement of FIM4 in human AML and MDS. Having documented by iPCR the presence of two insertions within Fim4 in a single tumor (No. 155), it is possible that both alleles are rendered nonfunctional and that Fim4 harbors a TSG. It is known that proviral insertions can render genes inactive. 50 ,51 analysis. An ideogram of the entire chromosome 7 and an enlargement of bands 31.1 to 36.3 are shown. The position of 12 sequence-tagged site PCR markers that were used in the LOH analysis are indicated, proportionally positioned along the ideogram based on the bp location given at http://www.ncbi.nlm.nih.gov/genome/sts/index.html. Markers for which there was loss of heterozygosity are indicated by 'del' in red, while retention of heterozygosity is indicated by 'het' in green. Those markers where no informative data are available are left blank. Shown are the data obtained by Koike et al 45 for three patients (Nos 16, 5 and 7) and by Kiuru-Kehlfelt et al 46 for three patients (Nos 1, 2 and 3). To the left is the minimally deleted region identified by FISH analysis by Le Beau et al. 43 Indeed, in a separate cohort of F-MuLV-induced myeloid leukemias now under analysis, we have identified a proviral insertion in the second intron of St7 (Yatsula and Perkins, unpublished), the mouse homolog of the TSG at 7q31.1 (Figure 4c 49 ). Further investigation is required to identify the gene at Fim4 and to assess its involvement in cases of human AML and MDS.
